Dornase alfa dry powder inhalation - MannKind Corporation
Alternative Names: Dornase alfa Technosphere® - MannKindLatest Information Update: 08 Dec 2020
At a glance
- Originator MannKind Corporation
- Class Antifibrotics; Enzymes; Recombinant proteins
- Mechanism of Action Deoxyribonuclease 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cystic fibrosis
Most Recent Events
- 24 Sep 2020 Dornase alfa dry powder inhalation - MannKind Corporation is available for licensing as of 24 Sep 2020. https://mannkindcorp.com/contact/
- 24 Sep 2020 Preclinical trials in Cystic fibrosis in USA (Inhalation) before September 2020 (MannKind Corporation pipeline, September 2020)